Travere Therapeutics CAO Sells Over $900K in Stock

Sandra Calvin, Chief Accounting Officer, reduces stake by 34% through pre-arranged trading plan

Apr. 18, 2026 at 8:40am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial banking equipment and machinery in shades of steel gray, bronze, and chrome, conceptually representing the complex financial infrastructure that underpins the modern economy.An insider sale by Travere Therapeutics' CAO highlights the complex financial machinery that drives the biotech industry.San Diego Today

Travere Therapeutics, Inc. (NASDAQ:TVTX) Chief Accounting Officer Sandra Calvin sold 21,977 shares of the company's stock on April 14th, 2026 for a total value of $902,595.39. The sale represented a 34.16% decrease in Calvin's position, leaving her with 42,353 shares valued at $1,739,437.71.

Why it matters

Insider transactions, especially by C-suite executives, can provide insights into a company's financial health and management's confidence in the business. This sale by the CAO may signal a shift in Travere's outlook or strategy, though the pre-arranged nature of the trade limits the conclusions that can be drawn.

The details

The shares were sold at an average price of $41.07 per share. Following the transaction, Calvin's ownership stake in Travere Therapeutics decreased from 51.5% to 34.16%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to schedule stock transactions in advance and avoid allegations of insider trading.

  • The shares were sold on Tuesday, April 14th, 2026.
  • The trade was disclosed in a legal filing with the SEC on April 18th, 2026.

The players

Sandra Calvin

Chief Accounting Officer of Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California, dedicated to developing and commercializing therapies for rare kidney and genetic disorders.

Got photos? Submit your photos here. ›

What they’re saying

“The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.”

— Sandra Calvin, Chief Accounting Officer

The takeaway

This insider sale by Travere's CAO, while executed through a pre-planned trading arrangement, may still raise questions about the company's near-term outlook and management's confidence in the business. Investors will likely monitor any further insider transactions and the company's financial performance in the coming quarters.